Apollo Hospitals — Splitting the Pharmacy Off While the Hospitals Compound

The State of Play

Apollo is India’s largest private hospital network and, bolted onto it, one of the country’s largest pharmacy-and-digital-health businesses. Through FY26 the company was doing two things at once: compounding a high-return hospital business (revenue ₹25,228 crore for the year, profit ₹2,003 crore) while engineering its biggest-ever corporate restructuring — a “composite scheme” to merge in a wholesale distributor (Keimed) and then demerge and separately list the entire pharmacy-plus-digital arm, Apollo HealthCo, by Q4 FY27. The hospitals held margins above 24% through a heavy bed-building phase; the digital business narrowed its losses sharply but pushed its breakeven date out by a quarter. The stock, at ~61 times earnings, prices in both the hospital compounding and the value the market expects the pharmacy spin-off to unlock.

The Company

Founded in 1983 by Dr Prathap C. Reddy as India’s first corporate hospital, Apollo runs three reporting verticals:

• Healthcare Services — the hospitals (the profit engine): ~73 hospitals, ~10,200 beds, the core of the franchise. Roughly half of group revenue but the overwhelming majority of profit.
• Apollo HealthCo — the omni-channel pharmacy distribution business, the Apollo 24|7 digital health platform, and (being merged in) the wholesale distributor Keimed. This is the entity slated to be carved out and listed.
• AHLL (Apollo Health & Lifestyle) — diagnostics, primary-care clinics, and specialty formats (Cradle, Spectra).

The hospital economics are strong and the lever set is familiar: occupancy (group ~67%, metros ~70%), case mix (the high-acuity “CONGO” specialties — cardiac, onco, neuro, gastro, ortho), and pricing/realisation. Mid-year, Apollo retired its ARPOB metric in favour of ARPP (average revenue per patient, ~₹1.8 lakh, growing ~9–10% — roughly half pricing, half richer case mix), arguing ARPOB was being misread as tariff inflation. The hospital arm earns a ~24–25% EBITDA margin and high-20s/30s return on capital.

Promoter holding is relatively low for a founder-led group at 28.02% (cut from a steady ~29.3% in September 2025), with foreign institutions the largest block (~42.6%) and domestic institutions rising (~22.8%). Leverage has stepped up over the three years to fund the bed expansion. Returns are healthy (ROCE ~17.9%, ROE ~22.1%) and the five-year profit CAGR is ~78%.

The Story So Far

The three annual reports establish the shape; the four calls (Q4 FY25 through Q3 FY26) are where the digital turn and the demerger play out.

The arc from the annual reports (FY23–FY25)

The hospitals were the steady core throughout (segment revenue rising ₹87,431 → 99,392 → 112,201 crore, in the AR’s units, profit climbing every year). The swing factor — and the real story of the period — was Apollo 24|7 / HealthCo: a segment that lost heavily, then turned. Its result went from a ₹2,465 crore loss to a ₹1,309 crore loss to a ₹1,127 crore profit, driven explicitly by cutting 24|7’s marketing and freight spend under an omni-channel shift. That digital-loss-to-profit turn is what carried consolidated pre-tax profit from ₹11,005 to ₹20,391 crore. FY25 then formalised two big forward commitments: a multi-year 4,300+ bed expansion at ~₹80,000 million (~₹8,000 crore), and the restructuring — demerging pharmacy + digital into a separately listed “NewCo,” with the parent keeping a 15% direct stake. The tone moved from brand storytelling (FY23) to operating discipline (FY24) to confident capital allocation (FY25), with leverage rising to fund it all.

Q4 & FY25 (call of 31 May 2025) — crossing ₹20,000 crore, the plan laid out

Apollo crossed ₹20,000 crore of revenue for the first time (FY25 ₹21,794 crore, +14%; profit ₹1,446 crore, +61%). Hospital margins held at 24.2%, and HealthCo’s digital cash loss had narrowed to ₹80 crore in the quarter. Management spelled out the build (₹8,000 crore for 4,300 beds over 3–4 years, ~₹6,000 crore still to spend) and the restructuring framing: Keimed to merge in over “15 months,” and HealthCo — retail pharmacy plus online plus Keimed — to be separately listed, targeting ₹25,000 crore of combined revenue at a 7% EBITDA margin (up from ~3.2% blended). On the threat from quick commerce, HealthCo CEO Madhivanan Balakrishnan was pointed:

“[Tying up with quick commerce] would relegate us to a back-office function… which Keimed is already doing.” — Madhivanan Balakrishnan, CEO, Apollo HealthCo (describing instead Apollo’s own “19-minute” delivery, then ~30% of GMV)

The headline forward promise: 24|7 cash breakeven between Q3 and Q4 FY26.

Q1 FY26 (call of 13 August 2025) — two metric changes, losses narrowing

Revenue grew 15% to ₹5,842 crore, profit 42%. Two reporting changes mattered for anyone tracking the series: ARPOB was retired for ARPP, and the digital GMV metric was redefined (counting only new-customer business for the hospital slice), breaking comparability. The digital loss narrowed further (₹73 crore vs ₹116 crore a year earlier). Crucially, the demerger structure was confirmed in detail — HealthCo (retail + online only; hospital pharmacies stay inside Healthcare Services) to be demerged and separately listed by Q4 FY27, with Keimed merging in via the composite scheme. New-hospital losses were quantified at a maximum ~₹150 crore over two years (a ~100 bps marginal dip to hospital margins), with management targeting a push of the base network toward 25%.

Q2 & H1 FY26 (call of 7 November 2025) — costs ahead of openings, GST noise

Revenue grew 13% to ₹6,304 crore. Hospital margin held at 24.6% despite over ₹67 crore of doctor-hiring costs running ahead of new-hospital openings (a ~₹120 crore cost-cut programme was the offset). Two women’s-and-specialty hospitals (Apollo Athenaa in Delhi, Pune) launched. The pipeline was reframed from “FY26” to “FY26–27.” On the digital side, a GST cut shaved ~6% off pharmacy top line (no profit impact) and made GMV growth look optically soft, but all three lines (pharmacy, diagnostics, consults) turned contribution-positive. Management reaffirmed 24|7 cash breakeven by end-FY26. Notably, the new-bed revenue contribution guidance had quietly softened — from “+10% over 2–3 years” (Q1) to “+5% over ~2 years.”

Q3 & 9M FY26 (call of 11 February 2026) — best print, breakeven slips, legal milestone

The December quarter was the best-balanced: revenue +17% to ₹6,477 crore, EBITDA +27%, profit +35%. Hospital margin rose to 24.8% (base network ~25.3%, with a stated path to ~26%+). The digital cash loss shrank to just ₹29 crore — “the lowest in any quarter by far.” But the breakeven promise slipped:

24|7 cash-EBITDA breakeven was pushed one quarter, to Q1 FY27 (from “end-FY26”), attributed to a post-GST insurance revenue-recognition mismatch deferring income — underlying indicators “on course.”

The restructuring, meanwhile, hit its most concrete legal milestone: CCI and SEBI approvals obtained, the composite scheme filed with the NCLT, and the NCLT hearing begun, with the ₹25,000 crore / 7% target reaffirmed. The new-bed revenue guidance softened again, to “+3–4% next year.”

How the promises tracked

• Hospital margin “maintain ~24%” → delivered (24.3% → 24.5% → 24.6% → 24.8%), base network ~25.3% with a path to 26%+.
• Digital losses narrowing as promised (cash loss ₹80 crore → ₹29 crore) — but the cash-breakeven date slipped from “Q3–Q4 FY26” to Q1 FY27.
• The demerger progressed from “15 months” framing to concrete legal status (CCI + SEBI cleared, NCLT hearing started); the ₹25,000 crore / 7% target held constant throughout. No swap ratio or listing mechanics disclosed yet.
• New-bed revenue contribution guidance crept down through the year (+10% → +5% → +3–4%) — worth flagging.
• GMV is hard to track — the metric was redefined twice, breaking the series; the clean read is online pharmacy growing ~30–32%.

Where Things Stand

As of the February 2026 call (with FY26 closing at ₹25,228 crore revenue and ₹2,003 crore profit per the snapshot), Apollo is executing two strategies in parallel. The hospital business is compounding well — mid-teens revenue growth, margins inching toward the high-24s with a base-network path to 26%+, and a large self-funded bed pipeline (~1,500 new operating beds due across FY27, first-year occupancy on new beds ~40%, breakeven on ~1,300 beds in ~2 years) that will create a known but bounded ~₹150 crore margin drag, to be reported separately from Q4 FY26. The digital/pharmacy business has done the hard part — turning crippling losses into near-breakeven — and is now the subject of the headline event: a composite scheme to merge in Keimed and separately list Apollo HealthCo by Q4 FY27, targeting ₹25,000 crore of revenue at a 7% margin, now cleared by the CCI and SEBI and before the NCLT. The open questions the next few quarters will answer: whether 24|7 actually reaches cash breakeven in Q1 FY27 (after one slip), how the new-hospital drag spreads through FY27, and the listing mechanics for HealthCo (swap ratio, record date) once the NCLT order lands. For a stock at ~61 times earnings, much of the thesis rests on the spin-off crystallising value the consolidated structure has been masking.

The Four Checks

1. Quality and moat. A genuinely good business with a strong, durable moat — in the hospitals. Forty years of brand equity as India’s first corporate hospital, ~10,200 beds across 73 hospitals, and the clinical-talent flywheel that brand sustains (when a star Delhi oncologist left for a peer, management’s answer — “the reverse is also happening” — is credible at Apollo’s scale). Metro hospital capacity is hard to replicate: land, licences, and a decade to build referral reputation. The pricing evidence is there too — ARPP growing ~9–10% a year, roughly half of it realisation. The pharmacy side is weaker: 6,600+ stores and ~8% of the organised market is scale, not a fortress, and quick commerce circles it. What erodes the moat is slow stuff — peer networks (Max, Manipal, Fortis) building in the same metros, and doctor mobility. Strong in the core, contestable at the edges.

2. Returns on incremental capital and runway. Blended ROCE is 17.9% and ROE 22.1%, but the blend understates the engine: the hospital segment’s reported ROCE ran 27.5%–38.4% across the four quarters covered, and that is where the incremental capital is going — ₹8,000 crore into 4,300 new beds over 3–4 years. The trend is up (operating margin 12% in FY23 to 15% in FY26; profit +33% in the latest year), and the runway is long: India remains structurally under-bedded, new hospitals break even in ~2 years on ~1,300 beds, and the pharmacy arm adds ~600 stores a year on top. High incremental returns, genuine room to deploy.

3. Capital allocation for the stage. Mostly textbook for a build phase. The bed programme is self-funded from cash flow (FY26 CFO ₹2,856 crore), phased to protect margins, with the drag bounded at ~₹150 crore; the dividend payout is kept modest (13–15%) while reinvestment dominates; equity capital is unchanged at ₹72 crore — growth funded without dilution, though borrowings have roughly doubled since FY23 to ₹8,493 crore. The strongest evidence is corrective: the digital business burned ~₹3,800 crore over FY23–24 before management cut marketing spend and turned it to profit, exited the loss-making Amazon channel, and is now demerging HealthCo so each business carries its own capital discipline. The quibbles: that digital bleed was permitted in the first place, no buyback history to judge, and the promoters trimmed their own stake by ~1.3 points in late 2025 during the run-up. Rational, with a learning curve behind it.

4. Price. Demanding. As of the June 2026 snapshot the stock trades at ₹8,580 — near its 52-week high — at 63 times earnings and 13 times book, with a 0.22% dividend yield, against ~16% revenue growth and 33% profit growth in FY26. The multiple already pays for the hospital compounding, the FY27 bed ramp landing on schedule, and the HealthCo spin-off unlocking value the consolidated structure has masked. A 22% ROE business at 13 times book leaves little margin for the breakeven date slipping again or the new-bed contribution guidance — already walked down from +10% to +3–4% — softening further. Priced for a lot to keep going right.

Sources

• Earnings-call transcripts read (4): Q4/FY25 (31 May 2025), Q1 FY26 (13 Aug 2025), Q2/H1 FY26 (7 Nov 2025), Q3/9M FY26 (11 Feb 2026). From screener/BSE-hosted filings.
• Annual reports read (high-signal sections): FY23, FY24, FY25.
• Financial snapshot: screener.in (consolidated, APOLLOHOSP), logged-out session, fetched 2026-06-07 — the source for FY26 full-year figures (revenue ₹25,228 crore, PAT ₹2,003 crore); the snapshot does not break out segment financials for the non-hospital businesses or disclose occupancy/ARPP (those come from the concalls).
• Research dump: vault/Sources/Earnings/Apollo Hospitals Enterprise Ltd/ (_profile_digest.md, _concall_digest.md, _ar_digest.md, raw transcripts, annual-report sections, _snapshot.json, _manifest.json). Not published.